- Home
- Your Messages
-
Smartest Doc
Daily Quiz CompetitionTest your clinical knowledge against other physicians in the USA by taking our FREE daily quiz!
New! PHYSICIAN REVIEW
Thousands of questions to assess your knowledge and aid exam prep!
- Physician Jobs (5062)
- More
- Other Specialty
Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer
BMC Cancer, 08/08/2012
Takeda M et al. – Patients in arm A will receive docetaxel at 60mg/m2 and those in arm B will receive docetaxel at 60mg/m2 plus bevacizumab at 15mg/kg, with each drug administered on day 1 every 21 days until progression or unacceptable toxicity. The primary endpoint of the study is progression–free survival, with secondary endpoints including response rate, overall survival, and safety, for patients treated in either arm.
Register now to view all the MDLinx contents (FREE)!
- Stay current on the latest literature, research and clinical news
- Get special communications and offers from MDLinx and our sponsors
- Receive invitations to paid market research
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Nurse Practitioner Jobs
@MDLinx Career Center
View the full listing of nursing jobs
Sponsor